BCDA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.030

Open

0.990

VWAP

0.97

Vol

887.12K

Mkt Cap

14.40M

Low

0.921

Amount

862.99K

EV/EBITDA(TTM)

--

Total Shares

14.88M

EV

13.45M

EV/OCF(TTM)

--

P/S(TTM)

--

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

Show More

Events Timeline

(ET)

2026-06-18

09:30:00

BioCardia CEO Updates Shareholders on Strategy and Priorities

2026-06-05 (ET)

2026-06-05

08:10:00

BioCardia Receives FDA Minutes on CardiAMP Meeting

2026-05-08 (ET)

2026-05-08

08:10:00

BioCardia's Helix Catheter System Receives FDA Approval Pathways

2026-04-20 (ET)

2026-04-20

08:20:00

BioCardia Reports Positive Clinical Consultation Outcome with Japan's PMDA

2026-04-02 (ET)

2026-04-02

10:20:00

BioCardia Submits CardiAMP HF Clinical Study Data to FDA

2026-03-17 (ET)

2026-03-17

06:10:00

BioCardia's Helix Catheter Pre-Submission Accepted by FDA

2026-03-03 (ET)

2026-03-03

08:20:00

BioCardia Reports Positive Results from Heart Failure Clinical Trial

2026-02-10 (ET)

2026-02-10

09:20:00

BioCardia Completes FDA Pre-Submission for Helix Catheter

2025-12-16 (ET)

2025-12-16

08:10:00

BioCardia Completes Third Clinical Consultation with Japan's PMDA

2025-12-03 (ET)

2025-12-03

08:20:00

BioCardia Appoints Marvin Slosman to Board of Directors

News

stocktwits

06-05stocktwits

BioCardia's Heart Failure Therapy Gains FDA Attention

NASDAQ.COM

06-05NASDAQ.COM

BioCardia's Heart Failure Trial Receives FDA Confirmation

Newsfilter

06-05Newsfilter

BioCardia Receives FDA Meeting Minutes Supporting Heart Failure Treatment

NASDAQ.COM

05-29NASDAQ.COM

BioCardia Receives Consultation Record from Japan's PDMA for CardiAMP Approval

Yahoo Finance

05-16Yahoo Finance

BioCardia Secures FDA Breakthrough Designation and Medicare Reimbursement

seekingalpha

05-15seekingalpha

BioCardia Q1 2026 Earnings Call Highlights

2 Analyst Rating

Wall Street analysts forecast BCDA stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

6.00

Averages

15.50

High

25.00

Current: 0.000

Low

6.00

Averages

15.50

High

25.00

No data

No data

Valuation Metrics

The current forward P/E ratio for BioCardia Inc (BCDA.O) is 0.00, compared to its 5-year average forward P/E of -2.78. For a more detailed relative valuation and DCF analysis to assess BioCardia Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.78

Current PE

0.00

Overvalued PE

-0.27

Undervalued PE

-5.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.14

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.32

Undervalued EV/EBITDA

-1.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

112.77

Current PS

0.00

Overvalued PS

309.83

Undervalued PS

-84.29

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

good penny stocks soon to blow up

Intellectia · 26 candidates

Market Cap: <= 300.00MPrice: $0.50 - $5.00Volume: >= 500,000Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceAboveMA60, PriceCrossAboveMA20

Ticker

Name

Market Cap$

Vivos Therapeutics Inc

12.01M

Eastern International Ltd

15.53M

BioCardia Inc

11.72M

YXT.Com Group Holding Ltd

32.36M

Scage Future

61.22M

Galaxy Payroll Group Ltd

6.62M

stock that trades 1.00 to 2.00 day trade

Intellectia · 211 candidates

Price: $1.00 - $2.00Rsi Category: moderateRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20

Ticker

Name

Market Cap$

Antelope Enterprise Holdings Ltd

2.63M

Soluna Holdings Inc

214.85M

Bit Digital, Inc

597.64M

Inovio Pharmaceuticals Inc

111.78M

American Bitcoin Corp

1.23B

Lexicon Pharmaceuticals Inc

746.09M

what’s the best three to buy right now

Intellectia · 1718 candidates

Region: USPrice Change Pct: >= $0.00Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20

Ticker

Name

Market Cap$

Mannatech Inc

9.01M

Antelope Enterprise Holdings Ltd

2.63M

Co-Diagnostics Inc

6.95M

BioCardia Inc

11.93M

Castellum Inc

62.12M

Token Cat Ltd

18.98M

Whales Holding BCDA

Trading Trends

People Also Watch

Frequently Asked Questions

What is BioCardia Inc (BCDA) stock price today?

The current price of BCDA is 0.9674 USD — it has increased 2.11

What is BioCardia Inc (BCDA)'s business?

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

What is the price predicton of BCDA Stock?

Wall Street analysts forecast BCDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCDA is15.50 USD with a low forecast of 6.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is BioCardia Inc (BCDA)'s revenue for the last quarter?

BioCardia Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is BioCardia Inc (BCDA)'s earnings per share (EPS) for the last quarter?

BioCardia Inc. EPS for the last quarter amounts to -0.21 USD, decreased -64.41

How many employees does BioCardia Inc (BCDA). have?

BioCardia Inc (BCDA) has 17 emplpoyees as of June 21 2026.

What is BioCardia Inc (BCDA) market cap?

Today BCDA has the market capitalization of 14.40M USD.